Corporate Banner
Satellite Banner
Biomolecular Screening
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Biousian Biosystems Receives US Patent

Published: Tuesday, December 17, 2013
Last Updated: Monday, December 16, 2013
Bookmark and Share
Patent provides composition of matter protection for a series of highly selective delta opioid receptor agonists.

Biousian Biosystems Inc, (BBI) has announced that the U.S. Patent and Trademark Office has issued a patent to BBI (U.S. Patent 8,575,309).

The patent describes a series of highly selective and potent delta opioid receptor agonists for the treatment of acute and chronic pain. One of the molecules covered by the patent is BBI-11008, the company’s lead drug that is positioned as a best-in-class analgesic.

BBI-11008 is an orally available drug that has equivalent efficacy to opioids but exhibits markedly reduced side effects in preclinical models. Due to the unique delta opioid selectivity of BBI-11008, it lacks the toxicities usually associated with mu selective opioid agonists (e.g. morphine), including respiratory distress, GI tract immobility and has no evidence of addiction. The molecule’s performance has been studied in extensive in-vivo preclinical pain studies, funded by multiple NIH SBIR grants.

Ed Bilsky, Founder of Biousian Biosystems and Professor of Biomedical Sciences at the University of New England, said, “Delta opioid receptors were first described in the 1970s, but multiple efforts to develop a highly selective agonist with drug-like properties have failed. Our novel synthetic chemistry applied to naturally occurring enkephalin opioid peptides enable us to impart small-molecule, drug-like properties to peptides. The lead molecule has therapeutic utility across a broad range of pain indications, including neuropathic pain, inflammatory pain, cancer pain and migraine.”

Robin Polt, Founder of Biousian Biosystems and Professor of Chemistry and Biochemistry, and BIO5 at the University of Arizona said, “We are very excited about the prospects for glycopeptide drugs that increase drug stability and increase penetration across the blood-brain barrier and into the central nervous system. Biologically compatible glycosides such as BBI-11008 are metabolized into simple amino acids and sugars that are more properly regarded as nutrients, in contrast to classical opioid alkaloids that produce a cascade of toxic metabolites.”

Mark Philip, acting President of Biousian Biosystems said “We are delighted to have made such rapid progress and achieved proof of principle for both efficacy and safety for BBI-11008 in a range of preclinical models. This, together with the recently-issued patent protection for this series of molecules, encourages us to accelerate the work towards moving the lead candidate into the clinic.”

Biousian is actively exploring both corporate partnerships and/or equity investment to progress this molecule into clinical trials. The company’s business development is being supported by Alacrita Consulting.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,300+ scientific posters on ePosters
  • More than 4,900+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.


Scientific News
Gene Terapy for Muscle Wasting Developed
New gene therapy could save millions of people suffering from muscle wasting disease.
Detecting Alzheimer's with Smell Test
Odour identification test may offer low-cost alternative for predicting cognitive decline and detecting early-stage Alzheimer’s disease.
Fighting Cancer Through Protein Pathways
Researchers have found a new drug target within a protein production pathway critical to regulating growth and proliferation of cells.
Mutations in DNA-Repair Genes Found in Advanced Prostate Cancers
New findings indicate that nearly 12% of male advanced prostate cancer sufferers have inherited mutation in DNA-repair genes.
Molecule May Affect Gaucher, Parkinson's Disease
Research has identified a molecule that restores activity of a dysfunctional enzyme linked to Gaucher and Parkinson's disease.
Targeting BRAF Mutations in Thyroid Cancer
Treating metastatic thyroid cancer patients harboring a BRAF mutation with vemurafenib showed anti-tumor activity in a third of patients.
Plant Compounds Fight Together Against Colon Cancer
Research shows treating colon cancer cells with curcumin, then silymarin is more effective than treatment with each individually.
New Centre Offers Ultra-Speed Protein Analysis
UW-Madison researchers to establish development centre for next-gen protein measurement technologies.
Drug Candidates Reduce Abnormal Protein Production
New drug candidates improve cell ability to catch miss-folded proteins that could cause deadly diseases.
Supercomputing and Drug Discovery
New biotech company uses supercomputer simulations to speed up drug discovery and biotech molecule development.
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,300+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,900+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!